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Evaluations were performed on 76 STEMI patients who underwent
PPCI at National Cardiac Center Harapan Kita (NCCHK) from February
2014 to August 2014. Patients were randomly classiﬁed into two
groups (Atorvastatin 80 mg and Placebo).Laboratory data on ICAM
were taken twice (0-hour and 24-hour post PPCI) and examined at
Prodia’s Laboratorium. Statistical analyses using SPSS were performed
to evaluate the effect of Atorvastatin treatment, which was measured
by delta ICAM.
RESULTS There were no difference between two groups (Atorvastatin
vs. Placebo) in terms of clinical, supporting data, and angiographic
ﬁndings. Delta ICAM values showed signiﬁcant difference between
two groups, which are Atorvastatin 80 mg (-13.038.5 ng/mL) and
Placebo (26.167.0 ng/mL, p 0.003). Linear regression analysis
(adjusted analysis; according to age, sex, diabetes, and renal insufﬁ-
ciency) showed coefﬁcient of -31.17 ng/mL with p 0.037.
CONCLUSION This study showed that acute Atorvastatin 80 mg
treatment pre-PPCI reduces endothelial inﬂammatory response which
was measured by ICAM.
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BACKGROUND Aneurysm expansion due to type 2 endoleak is one of
the major troubles after endovascular aneurysm repair (EVAR). Long-
term outcome about persistent type 2 endoleak is still unclear. The
aim of this study is to evaluate the clinical signiﬁcance of persistent
type II Endoleak and feasibility of additional coil embolization in
patients with abdominal aortic aneurysm (AAA) after EVAR.
METHODS We retrospectively analyzed consecutive 236 patients un-
derwent EVAR for abdominal aortic aneurysm in Kyoto university
hospital, between March 2003 and June 2014.
RESULTS Mean age was 75.97.6 years old and 194 cases (82%) was
male. Mean follow up period was 1021687 days. Persistent type II
endoleak was observed in 28 cases (11.9%). Fifteen cases were
Excluder, 11cases were Zenith and 2 cases was Power link. Aneurysm
expansion than 5mm was more often observed in patient with type II
endoleak (25% vs. 2%). We performed Coil embolization for 14 cases
due to aneurysm expansion larger than 5mm. One case need surgical
conversion due to aneurysm expansion and failed coil embolization.
After coil embolization, aneurysm expansion was stopped or
decreased in 12 cases (85%).
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BACKGROUND The clinical outcomes of EVT for the restenosis of SFA
stent with jailed DFA were poorly understood. The aim of this study
was to reveal the SFA patency and the fate of DFA after EVT for the
restenosis of SFA stent with jailed DFA.
METHODS From April 2007 to January 2013, we performed de novo
490 ostial SFA stenting with jailed DFA. Of these, restenosis had
occurred in the 32 lesions of 19 patients. We performed ballooning or
stenting for the SFA restenosis and compared the clinical outcomes at
1, 6, and 12 month.
RESULTS There were no signiﬁcant differences in the patient back-
ground and characteristics between the two groups. Overall primary
patency was 96.7%, 87.1% and 58.3%, assisted primary patency
was 100%, 90.3% and 80.0%,freedom from MALE was 96.9%,
90.3%,and 83.3%, and DFA patency was 96.7%,93.3%,and 93.1% at 1, 6
and 12 month. Primary patency at 12month tend to be lower in the
ballooning (47.1% versus 85.7%, p¼0.06) and assisted primary
patency at 12 month was signiﬁcantly lower in ballooning than
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 5 , N O . 1 7 , S U P P L S , 2 0 1 5 S51stenting. (73%versus 100%, p¼0.05) However, there was no signiﬁcant
difference in freedom from MALE and DFA patency. (N.S.)
CONCLUSION The results of stenting for in stent restenosis of SFA
with jailed DFA were favorable than ballooning and the 12 month fate
of DFA was acceptable in this study.
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BACKGROUND Ectatic and aneurysmal iliac arteries adversely affect
the treatment and long-term results of EVAR. Objective of the study is
to evaluate the use of novel technology to treat complex aortic
aneurysms involving iliac arteries. We reviewed our ﬁrst experience
with an unique endoprosthesis which is designed to treat aneurysms
by ﬁlling the aneurysm sac with a quick-setting polymer. Polymer is
contained in endobag surrounding the endoprothesis. The ﬁlled
endobags obliterate the aneurysm sac while providing support and
stability to the ﬂow lumens. With the new technology aneurysmal
iliac arteries are treated keeping internal iliac arteries patent.METHODS Patients with aorto-iliac aneurysms treated in our center
using the Nellix (Endologix, Inc.) endograft were reviewed. Patients
were treated in catheterization laboratory under regional or general
anaesthesia using femoral artery approach. Analyses were conducted
in accordance with the endovascular aneurysm reporting standards.
Follow-up studies accrued at discharge, one, 6, and 12 months, and
included computed tomography angiography and duplex ultrasound
angiography scans, and ﬂat plate radiography.
